In the world of obesity research, the arrival of GLP-1 drugs like Ozempic feels seismic. At a recent conference, Martin Binks, a leader in obesity research, found himself marveling with a colleague: “Can you believe we finally reached this moment, that we lived long enough to see this?”
This article was originally published on MedicalXpress.com

